2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on BRAFV600E mCRC: How Effective Is FDA Approved 2L Encorafenib + Cetuximab?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Chloe Atreya
By 2020 ASCO Virtual Direct™ Highlights FEATURING Chloe Atreya
79 views
August 20, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
GI
11:26
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced HCC: Is Novel Tremelimumab/Durvalumab R…

Feat. K. Wong
06:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable Pancreatic Ductal Adenocarcinoma: Is …

Feat. K. Wong
07:07
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable GE Adenocarcinoma: Does Perioperative…

Feat. K. Wong
06:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Esophageal Adenocarcinoma: Does the Additi…

Feat. K. Wong
07:24
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III CRC: Are Patients with Stage III Colon…

Feat. C. Atreya
06:09
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BRAFV600E mCRC: How Effective Is FDA Approved 2L…

Feat. C. Atreya
10:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ mCRC: Did Trastuzumab Deruxtecan Demonstra…

Feat. C. Atreya
07:34
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Data on Pembro vs. Chemo in MSI-H mCRC: Is There a Clinica…

Feat. C. Atreya